AllCells, LLC Forms Scientific Advisory Board

EMERYVILLE, Calif.--(BUSINESS WIRE)--AllCells, LLC, a leading global provider of hematology and immunology based primary cells and related services for drug discovery, toxicology, stem cell research, and other life science applications today announced the appointment of its first Scientific Advisory Board (SAB). The new SAB members include:

“AllCells has experienced steady growth during the past several years and the newly created SAB is an important milestone in the company’s development. The SAB is expected to strengthen AllCells’ ability to identify and assess strategic opportunities that fit squarely with the company’s core competencies”

Linzhao Cheng, PhD - Professor of Medicine and a founding member of the Stem Cell Program in the Johns Hopkins Institute for Cell Engineering, JHU School of Medicine (JHUSOM), Baltimore, MD. He is also the Associate Director for Basic Research, Division of Hematology, and a faculty member in PhD Training Programs in Cellular & Molecular Medicine, Human Genetics and Immunology in JHUSOM. Dr. Cheng will serve as Chairman of AllCells’ SAB.

Ronald Hoffman, MD - Professor of Medicine at the Mount Sinai School of Medicine, New York, NY, Co-Director, Myeloid Malignancy Program (MPP) of the Tisch Cancer Institute (TCI), Mount Sinai School of Medicine, Principal Investigator of the Myeloproliferative Research Consortium (MPD-RC) - a program project grant funded by the NCI, and a former President of the American Society of Hematology.

Timothy C. Fong, PhD, MBA - Vice President, Technology and Product Development at Progenitor Cell Therapy (a NeoStem, Inc. company), Mountain View, CA. He is the former Technical Director, Cell Therapy, and Director of the BD Cell Therapy initiative at BD Biosciences, VP Research at Cellerant Therapeutics, and VP Discovery Research at Sangstat Medical Corp.

AllCells’ President and Chief Executive, Jay Tong, MD, commented, “These outstanding scientific leaders together offer broad knowledge and expertise in the fields of hematology, immunology, cancer research, and stem cell science. Their contributions will be vitally important for shaping the future direction of AllCells’ products and services which serve the life science community.”

“AllCells has experienced steady growth during the past several years and the newly created SAB is an important milestone in the company’s development. The SAB is expected to strengthen AllCells’ ability to identify and assess strategic opportunities that fit squarely with the company’s core competencies,” added Wayne Vaz, Vice President of Corporate Development.

About AllCells, LLC

AllCells (www.AllCells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications where in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce time needed to isolate cells with guaranteed consistency thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements.